BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 23035693)

  • 1. Quality of life in raloxifene-treated Japanese women with postmenopausal osteoporosis: a prospective, postmarketing observational study.
    Yoh K; Hamaya E; Urushihara H; Iikuni N; Yamamoto T; Taketsuna M; Miyauchi A; Sowa H; Tanaka K
    Curr Med Res Opin; 2012 Nov; 28(11):1757-66. PubMed ID: 23035693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quality of life in Japanese women with postmenopausal osteoporosis treated with raloxifene and vitamin D: post hoc analysis of a postmarketing study.
    Ohta H; Hamaya E; Taketsuna M; Sowa H
    Curr Med Res Opin; 2015 Jan; 31(1):85-94. PubMed ID: 25299349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Skeletal pain in postmenopausal women with osteoporosis: prevalence and course during raloxifene treatment in a prospective observational study of 6 months duration.
    Scharla S; Oertel H; Helsberg K; Kessler F; Langer F; Nickelsen T
    Curr Med Res Opin; 2006 Dec; 22(12):2393-402. PubMed ID: 17257453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Raloxifene in clinical practice. Results of the non-interventional study CORAL (COmpliance with RALoxifene)].
    Rosa J; Vanuga P; Payer J; Svobodník A
    Vnitr Lek; 2008 Mar; 54(3):217-9, 221-4. PubMed ID: 18522288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Responsiveness of the Japanese Osteoporosis Quality of Life questionnaire in women with postmenopausal osteoporosis.
    Urushihara H; Yoh K; Hamaya E; Taketsuna M; Tanaka K
    Health Qual Life Outcomes; 2014 Dec; 12():178. PubMed ID: 25495650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of 3-year raloxifene treatment in Japanese postmenopausal women aged 75 years or older with osteoporosis: a postmarketing surveillance study.
    Takeuchi Y; Hamaya E; Taketsuna M; Sowa H
    Menopause; 2015 Oct; 22(10):1134-7. PubMed ID: 25756692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Raloxifene and stroke risks in Japanese postmenopausal women with osteoporosis on postmarketing surveillance.
    Urushihara H; Kikuchi N; Yamada M; Yoshiki F; Miyauchi A
    Menopause; 2009; 16(5):971-7. PubMed ID: 19357545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the sexual function and quality of life in raloxifene treated postmenopausal women.
    Biri A; Korucuoglu U; Ilhan MN; Ciftci B; Bozkurt N; Guner H
    Arch Gynecol Obstet; 2009 Apr; 279(4):505-9. PubMed ID: 18690468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of teriparatide in postmenopausal women with osteoporosis and glucocorticoid use: 3-year results from the EFOS study.
    Karras D; Stoykov I; Lems WF; Langdahl BL; Ljunggren Ö; Barrett A; Walsh JB; Fahrleitner-Pammer A; Rajzbaum G; Jakob F; Marin F
    J Rheumatol; 2012 Mar; 39(3):600-9. PubMed ID: 22247365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between bone mass, invasive breast cancer incidence and raloxifene therapy in postmenopausal women with low bone mass or osteoporosis.
    Burshell AL; Song J; Dowsett SA; Mershon JL; Delmas PD; Secrest RJ; Cauley JA
    Curr Med Res Opin; 2008 Mar; 24(3):807-13. PubMed ID: 18254988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Back pain during different sequential treatment regimens of teriparatide: results from EUROFORS.
    Lyritis G; Marin F; Barker C; Pfeifer M; Farrerons J; Brixen K; del Pino J; Keen R; Nickelsen TN;
    Curr Med Res Opin; 2010 Aug; 26(8):1799-807. PubMed ID: 20482322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study.
    Siris ES; Harris ST; Eastell R; Zanchetta JR; Goemaere S; Diez-Perez A; Stock JL; Song J; Qu Y; Kulkarni PM; Siddhanti SR; Wong M; Cummings SR;
    J Bone Miner Res; 2005 Sep; 20(9):1514-24. PubMed ID: 16059623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health-related quality of life in postmenopausal women with low BMD with or without prevalent vertebral fractures.
    Oleksik A; Lips P; Dawson A; Minshall ME; Shen W; Cooper C; Kanis J
    J Bone Miner Res; 2000 Jul; 15(7):1384-92. PubMed ID: 10893688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of raloxifene on cardiac autonomic regulation in osteoporotic women.
    Gol M; Baris N; Guneri S; Posaci C
    Am J Obstet Gynecol; 2006 May; 194(5):1249-54. PubMed ID: 16647907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene.
    McClung MR; Siris E; Cummings S; Bolognese M; Ettinger M; Moffett A; Emkey R; Day W; Somayaji V; Lee A
    Menopause; 2006; 13(3):377-86. PubMed ID: 16735934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of patients with an inadequate clinical outcome from osteoporosis therapy: the Observational Study of Severe Osteoporosis (OSSO).
    Jakob F; Marín F; Martín-Mola E; Torgerson D; Fardellone P; Adami S; Thalassinos NC; Sykes D; Melo-Gomes J; Chinn C; Nicholson T; Cooper C
    QJM; 2006 Aug; 99(8):531-43. PubMed ID: 16861718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adiponectin and leptin serum levels in osteoporotic postmenopausal women treated with raloxifene or alendronate.
    Sebastián-Ochoa A; Fernández-García D; Reyes-García R; Mezquita-Raya P; Rozas-Moreno P; Alonso-Garcia G; Muñoz-Torres M
    Menopause; 2012 Feb; 19(2):172-7. PubMed ID: 21971209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Raloxifene plus ossein-hydroxyapatite compound versus raloxifene plus calcium carbonate to control bone loss in postmenopausal women: a randomized trial.
    Pelayo I; Haya J; De la Cruz JJ; Seco C; Bugella JI; Diaz JL; Bajo JM; Repolles M
    Menopause; 2008; 15(6):1132-8. PubMed ID: 18791486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial.
    Deal C; Omizo M; Schwartz EN; Eriksen EF; Cantor P; Wang J; Glass EV; Myers SL; Krege JH
    J Bone Miner Res; 2005 Nov; 20(11):1905-11. PubMed ID: 16234962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of depressive symptoms in postmenopausal women with low bone mineral density and/or prevalent vertebral fracture: results from the Multiple Outcomes of Raloxifene Evaluation (MORE) study.
    Silverman SL; Shen W; Minshall ME; Xie S; Moses KH
    J Rheumatol; 2007 Jan; 34(1):140-4. PubMed ID: 17216681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.